Ad hoc-Mitteilungen

Relief Therapeutics Expands U.S. Commercial Team

| Aufrufe: 310

Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Expands U.S. Commercial Team 23-May-2022 / 06:55 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

Relief Therapeutics Expands U.S. Commercial Team Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, Respectively

Seasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare Diseases Geneva, Switzerland, May 23, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced today the appointments, effective May 23, 2022, of Tracy Truong and Kelli Powell, as Regional Clinical Specialists for the West and Northeast Regions, respectively. Both Ms. Truong and Ms. Powell will report directly to Chris Wick, Executive Director and Head of U.S. Sales.

“As highly accomplished, proven pharmaceutical sales leaders who bring deep expertise from careers spent at top-tier firms including Alexion, Bristol-Myers Squibb, Genzyme, Shire/NPS Pharmaceuticals and others, Tracy and Kelli will be integral members of the Relief commercial team and their appointments reflect our continued commitment to building out our U.S. operations,” stated Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations of Relief. “Their passion for serving the needs of patients, coupled with their extensive experience in rare diseases, will enable them to make significant and lasting contributions to the future of our company. We look forward to leveraging their knowledge and industry relationships for the anticipated rollout of PKU GOLIKE®, the flagship product line of our wholly owned subsidiary, APR Applied Pharma Research, SA (APR), and for the potential launch of ACER-001, for the treatment of Urea Cycle Disorders, in collaboration with Acer Therapeutics, which has an upcoming June 5, 2022 Prescription Drug User Fee Act (PDUFA) date.”

Additional features: File: Ad hoc release
End of ad hoc announcement
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Phone: +41 22 545 11 16
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1358287
End of Announcement EQS News Service

1358287  23-May-2022 CET/CEST

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Relief Therap.
0,032 $